FUNDAMENTALS · Fundamentals · US Healthcare

BioMarin Pharmaceutical (BMRN) Fundamentals 2026 — P/E 41.7x, Revenue Analysis | SniperIQ

BioMarin Pharmaceutical (BMRN) is a US-listed Healthcare company in Biotechnology with a market capitalization of

1.3B, trading at $58.42 on the NASDAQ. This SniperIQ fundamentals page covers BioMarin Pharmaceutical's valuation (P/E 41.7x, P/B 1.8x), profitability (net margin 8.3%), revenue (
.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
1.3B
P/E (TTM)41.7x
Net Margin8.3%
Revenue (FY25)
.2B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is BioMarin Pharmaceutical's market cap?

BioMarin Pharmaceutical (BMRN) has a market capitalization of approximately

1.3B, trading at $58.42 on the NASDAQ. Market cap moves with the live share price.

What is BioMarin Pharmaceutical's P/E ratio?

BioMarin Pharmaceutical's trailing twelve-month P/E ratio is 41.7x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is BioMarin Pharmaceutical?

BioMarin Pharmaceutical runs a net profit margin of 8.3%, a gross margin of 75.9%, and an operating margin of 13.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does BioMarin Pharmaceutical generate?

BioMarin Pharmaceutical reported revenue of

.2B for fiscal year 2025, with net income of
49M and earnings per share (EPS) of 1.82. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does BioMarin Pharmaceutical pay a dividend?

BioMarin Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is BioMarin Pharmaceutical financially healthy?

BioMarin Pharmaceutical carries a debt-to-equity ratio of 0.23x and a current ratio of 5.81x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is BioMarin Pharmaceutical a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BioMarin Pharmaceutical (BMRN) the key facts are: market cap

1.3B, P/E 41.7x, revenue
.2B, 52-week range 49.26-66.28. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track BioMarin Pharmaceutical's full fundamentals live

Get BioMarin Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.